Popular Trials
Thromboxane A2 Receptor Antagonist
Oral Ifetroban for Scleroderma
This trial is testing ifetroban, an oral medication, in patients with severe forms of systemic sclerosis. The goal is to see if it can reduce inflammation and improve blood flow, potentially helping to manage their condition better.
Prostacyclin Analogue
Treprostinil for Pulmonary Arterial Hypertension
This trial will study the effects of a medication called treprostinil on people with pulmonary arterial hypertension. The goal is to see if the medication can lower the pressure in the arteries of the lungs and improve the function of the right ventricle of the heart.
Prostacyclin Analogue
Treprostinil Palmitil for Pulmonary Arterial Hypertension
This trial is testing an inhalable medicine called TPIP to see if it can help people with high blood pressure in their lungs by making it easier for blood to flow through their lung arteries.
Popular Filters
Trials for PAH Patients
Biguanides
Metformin + mHealth for Pulmonary Arterial Hypertension
This trial is testing two interventions to see if they can improve insulin resistance in people with pulmonary artery hypertension. The primary endpoint is a 10% improvement in the distance the person can walk in six minutes, or an improvement in the person's functional class according to the World Health Organization.
Prostacyclin Receptor Agonist
Selexipag for Pulmonary Arterial Hypertension
This trial aims to find the right dose of Selexipag for children with Pulmonary Arterial Hypertension (PAH). Selexipag helps by relaxing lung blood vessels, lowering blood pressure, and improving blood flow. The goal is to ensure the treatment is safe and effective for younger patients.
Vascular Function in Pulmonary Arterial Hypertension
This trial is designed to study changes in vascular function with advancing age, and also examine peripheral vascular changes in patients suffering from chronic obstructive pulmonary disease (COPD), Sepsis, Pulmonary Hypertension, and cardiovascular disease.
Trials for PH Patients
Device
Aria CV System for Pulmonary Arterial Hypertension
This trial is testing a new device called the Aria CV PH System, which helps manage high blood pressure in the lungs and supports heart function. It is aimed at patients with pulmonary hypertension and related heart issues. The study will check if the device is safe and effective over a period of several months to a few years.
Prostacyclin Analog
L606 Inhalation Suspension for Pulmonary Arterial Hypertension
This trial tests a new medication called L606 in patients with specific types of lung disease. It aims to see if L606 is safe, helps patients breathe better, and improves their quality of life compared to an existing treatment called Tyvaso. LIQ861 is a novel dry-powder formulation of treprostinil, similar to the inhaled, nebulized treprostinil (Tyvaso®).
Gas
Xenon MRI for Pulmonary Arterial Hypertension
This trial uses a special MRI scan with a gas to monitor lung function in patients with severe lung disease. It targets those being monitored over time to better understand and track their condition. The MRI technique provides detailed lung function measurements and is well-tolerated, allowing for thorough exploration of lung function.
Phase 3 Trials
Endothelin Receptor Antagonist
Macitentan for Pulmonary Hypertension
This trial is testing macitentan, a drug that helps lower lung blood pressure, in children with pulmonary arterial hypertension. Macitentan has shown significant effectiveness in improving the condition of patients with pulmonary arterial hypertension.
Endothelin Receptor Antagonist
High-Dose Macitentan for PAH
This trial is testing if a higher dose of macitentan can better help patients with pulmonary arterial hypertension by improving blood flow in their lungs. Macitentan has shown promise in helping patients by slowing down the disease and improving their health.
Sotatercept for Pulmonary Arterial Hypertension
This trial is testing sotatercept added to current treatments for patients with severe PAH who are at high risk of death. The goal is to see if it can lower lung blood pressure and improve patient outcomes. Sotatercept, which modulates bone morphogenic protein receptor type 2 (BMPR2) signaling, showed promising results in earlier studies.
Trials With No Placebo
Prostacyclin Receptor Agonist
Selexipag for Pulmonary Arterial Hypertension
This trial aims to find the right dose of Selexipag for children with Pulmonary Arterial Hypertension (PAH). Selexipag helps by relaxing lung blood vessels, lowering blood pressure, and improving blood flow. The goal is to ensure the treatment is safe and effective for younger patients.
Vascular Function in Pulmonary Arterial Hypertension
This trial is designed to study changes in vascular function with advancing age, and also examine peripheral vascular changes in patients suffering from chronic obstructive pulmonary disease (COPD), Sepsis, Pulmonary Hypertension, and cardiovascular disease.
Endothelin Receptor Antagonist
Macitentan for Pulmonary Hypertension
This trial is testing macitentan, a drug that helps lower lung blood pressure, in children with pulmonary arterial hypertension. Macitentan has shown significant effectiveness in improving the condition of patients with pulmonary arterial hypertension.
View More Related Trials
Frequently Asked Questions
Introduction to pulmonary arterial hypertension
What are the top hospitals conducting pulmonary arterial hypertension research?
When it comes to cutting-edge clinical trials in the field of pulmonary arterial hypertension, several top hospitals are leading the way. In Saint Louis, Washington University School of Medicine is at the forefront with seven ongoing trials focused on this condition. This renowned institution is dedicated to pushing the boundaries of knowledge and treatment for pulmonary arterial hypertension. Similarly, Duke University Medical Center in Durham has also embarked on seven active clinical trials in pursuit of better therapies for this challenging disease. With a reputation for excellence in research and patient care, they strive to make significant advancements in understanding and managing pulmonary arterial hypertension.
In Kansas City, the University of Kansas Medical Center has six ongoing studies aimed at improving outcomes for patients with pulmonary arterial hypertension. They are committed to finding innovative solutions that can enhance quality of life and prolong survival rates among those affected by this rare condition. Meanwhile, Vanderbilt University Medical Center located in Nashville shares a similar dedication as they too conduct six active clinical trials specifically addressing pulmonary arterial hypertension. Their efforts contribute significantly to unraveling new insights into this complex disease.
Finally, The Ohio State University Wexner Medical Center located in Columbus rounds out our list with five currently ongoing clinical trials focusing on pulmonary arterial hypertension. Their commitment demonstrates their passion for advancing medical knowledge surrounding this condition while striving towards more effective treatments.
Though these hospitals have yet to complete any past trials specific to pulmonary arterial hypertension (PAH), their current endeavors send an encouraging message that researchers across multiple prestigious institutions are actively working towards improving outcomes for PAH patients worldwide through groundbreaking investigations
Which are the best cities for pulmonary arterial hypertension clinical trials?
When it comes to pulmonary arterial hypertension clinical trials, several cities have emerged as leading centers for research and development. Los Angeles, California leads the way with 29 active trials exploring treatments like Ralinepag, AV-101, and Treprostinil Inhalation Powder. Boston, Massachusetts closely follows with 23 ongoing studies focused on innovative approaches such as Ralinepag and Sotatercept. New york, New York also plays a significant role in advancing treatment options with 18 active trials investigating therapies like GB002 (seralutinib) and Macitentan 75 mg. Additionally, Cincinnati, Ohio and Houston, Texas both contribute to the field of pulmonary arterial hypertension research through their respective 15 active trials. These cities offer individuals living with this condition access to cutting-edge clinical trials that pave the way for advancements in care and provide hope for improved outcomes.
Which are the top treatments for pulmonary arterial hypertension being explored in clinical trials?
Pulmonary arterial hypertension (PAH) is a challenging condition, but ongoing clinical trials bring hope for new treatments. The top contenders in these trials include:
- Selexipag: Being explored in 8 active PAH trials and has been listed since 2015.
- Riociguat: Under investigation in 6 current studies for PAH, with its first listing dating back to 2007.
- Macitentan: Engaged in 4 active PAH trials and has been part of the research landscape since 2009.
These cutting-edge therapies are paving the way towards improved management and outcomes for individuals living with pulmonary arterial hypertension.
What are the most recent clinical trials for pulmonary arterial hypertension?
Exciting advancements are being made in the field of pulmonary arterial hypertension (PAH) through recent clinical trials. One notable trial investigates the efficacy of hyperpolarized 129Xe, offering potential insights into new treatment approaches for PAH patients. Another study focuses on healthy volunteers to gain a better understanding of this condition and improve diagnostic techniques. Additionally, researchers are evaluating the use of Treprostinil Palmitil Inhalation Powder (TPIP) in both Phase 2 and Phase 3 trials, aiming to provide an innovative therapeutic option for individuals with PAH. Furthermore, investigations also extend to pediatric populations aged ≥1 to <18 years old as they strive to enhance care tailored specifically towards younger patients. Lastly, a promising Phase 3 trial explores the potential benefits of low-dose AV-101 for those living with PAH. These cutting-edge studies offer hope for improved treatments that can positively impact the lives of individuals affected by PAH.
What pulmonary arterial hypertension clinical trials were recently completed?
Several recent clinical trials have made significant progress in the field of pulmonary arterial hypertension, offering hope for patients with this challenging condition. Notably, a trial conducted by United Therapeutics Corporation investigating Ralinepag reached completion in December 2021. Another important study sponsored by Actelion Pharmaceuticals explored the efficacy of Macitentan and concluded in September 2021. Furthermore, Merck Sharp & Dohme Corp completed their trial evaluating Vericiguat as a potential treatment option for pulmonary arterial hypertension in May 2021. These advancements represent promising steps forward in improving outcomes and quality of life for individuals living with this debilitating disease.